[{"orgOrder":0,"company":"Vaxcyte","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"24-valent Pneumococcal Conjugate Vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vaxcyte","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Vaxcyte \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaxcyte \/ Not Applicable"},{"orgOrder":0,"company":"Vaxcyte","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"24-valent Pneumococcal Conjugate Vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vaxcyte","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Vaxcyte \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaxcyte \/ Not Applicable"},{"orgOrder":0,"company":"Vaxcyte","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"24-valent Pneumococcal Conjugate Vaccine","moa":"Opsonophagocytosis","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vaxcyte","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Vaxcyte \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaxcyte \/ Not Applicable"},{"orgOrder":0,"company":"Vaxcyte","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"24-valent Pneumococcal Conjugate Vaccine","moa":"Opsonophagocytosis","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vaxcyte","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Vaxcyte \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaxcyte \/ Not Applicable"},{"orgOrder":0,"company":"Vaxcyte","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"24-valent Pneumococcal Conjugate Vaccine","moa":"Opsonophagocytosis","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vaxcyte","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Vaxcyte \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaxcyte \/ Not Applicable"},{"orgOrder":0,"company":"Vaxcyte","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2022","type":"Public Offering","leadProduct":"24-valent Pneumococcal Conjugate Vaccine","moa":"Opsonophagocytosis","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vaxcyte","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.57999999999999996,"dosageForm":"Injectable\/Injection","sponsorNew":"Vaxcyte \/ BofA Securities","highestDevelopmentStatusID":"8","companyTruncated":"Vaxcyte \/ BofA Securities"},{"orgOrder":0,"company":"Vaxcyte","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"24-valent Pneumococcal Conjugate Vaccine","moa":"Opsonophagocytosis","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vaxcyte","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Vaxcyte \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaxcyte \/ Not Applicable"},{"orgOrder":0,"company":"Vaxcyte","sponsor":"Sutro Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2022","type":"Agreement","leadProduct":"24-valent Pneumococcal Conjugate Vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vaxcyte","amount2":0.16,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.16,"dosageForm":"Injectable\/Injection","sponsorNew":"Vaxcyte \/ Vaxcyte","highestDevelopmentStatusID":"8","companyTruncated":"Vaxcyte \/ Vaxcyte"},{"orgOrder":0,"company":"Vaxcyte","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2023","type":"Not Applicable","leadProduct":"24-valent Pneumococcal Conjugate Vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vaxcyte","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Vaxcyte \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaxcyte \/ Not Applicable"},{"orgOrder":0,"company":"Vaxcyte","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2023","type":"Not Applicable","leadProduct":"24-valent Pneumococcal Conjugate Vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vaxcyte","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Vaxcyte \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaxcyte \/ Not Applicable"},{"orgOrder":0,"company":"Vaxcyte","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2023","type":"Not Applicable","leadProduct":"24-valent Pneumococcal Conjugate Vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vaxcyte","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Vaxcyte \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaxcyte \/ Not Applicable"},{"orgOrder":0,"company":"Vaxcyte","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2023","type":"Public Offering","leadProduct":"24-valent Pneumococcal Conjugate Vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vaxcyte","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.57999999999999996,"dosageForm":"Injectable\/Injection","sponsorNew":"Vaxcyte \/ BofA Securities","highestDevelopmentStatusID":"8","companyTruncated":"Vaxcyte \/ BofA Securities"},{"orgOrder":0,"company":"Vaxcyte","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2023","type":"Public Offering","leadProduct":"24-valent Pneumococcal Conjugate Vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vaxcyte","amount2":0.5,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.57999999999999996,"dosageForm":"Injectable\/Injection","sponsorNew":"Vaxcyte \/ BofA Securities","highestDevelopmentStatusID":"8","companyTruncated":"Vaxcyte \/ BofA Securities"},{"orgOrder":0,"company":"Vaxcyte","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2023","type":"Public Offering","leadProduct":"24-valent Pneumococcal Conjugate Vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vaxcyte","amount2":0.57999999999999996,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.57999999999999996,"dosageForm":"Injectable\/Injection","sponsorNew":"Vaxcyte \/ BofA Securities","highestDevelopmentStatusID":"8","companyTruncated":"Vaxcyte \/ BofA Securities"},{"orgOrder":0,"company":"Vaxcyte","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2023","type":"Not Applicable","leadProduct":"24-valent Pneumococcal Conjugate Vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vaxcyte","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Vaxcyte \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaxcyte \/ Not Applicable"},{"orgOrder":0,"company":"Vaxcyte","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2023","type":"Not Applicable","leadProduct":"24-valent Pneumococcal Conjugate Vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vaxcyte","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Vaxcyte \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaxcyte \/ Not Applicable"},{"orgOrder":0,"company":"Vaxcyte","sponsor":"Lonza Group","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2023","type":"Expanded Collaboration","leadProduct":"24-valent Pneumococcal Conjugate Vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vaxcyte","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Vaxcyte \/ Vaxcyte","highestDevelopmentStatusID":"8","companyTruncated":"Vaxcyte \/ Vaxcyte"},{"orgOrder":0,"company":"Vaxcyte","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2023","type":"Not Applicable","leadProduct":"31-valent Pneumococcal Conjugate Vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Vaxcyte","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Vaxcyte \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Vaxcyte \/ Not Applicable"},{"orgOrder":0,"company":"Vaxcyte","sponsor":"Sutro Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2023","type":"Agreement","leadProduct":"24-valent Pneumococcal Conjugate Vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vaxcyte","amount2":0.14000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.16,"dosageForm":"Injection","sponsorNew":"Vaxcyte \/ Vaxcyte","highestDevelopmentStatusID":"8","companyTruncated":"Vaxcyte \/ Vaxcyte"},{"orgOrder":0,"company":"Vaxcyte","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2023","type":"Not Applicable","leadProduct":"31-valent Pneumococcal Conjugate Vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Vaxcyte","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Vaxcyte \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Vaxcyte \/ Not Applicable"},{"orgOrder":0,"company":"Vaxcyte","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2024","type":"Not Applicable","leadProduct":"31-valent Pneumococcal Conjugate Vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Vaxcyte","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Vaxcyte \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Vaxcyte \/ Not Applicable"},{"orgOrder":0,"company":"Vaxcyte","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2024","type":"Not Applicable","leadProduct":"31-valent Pneumococcal Conjugate Vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Vaxcyte","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Vaxcyte \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Vaxcyte \/ Not Applicable"},{"orgOrder":0,"company":"Vaxcyte","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2024","type":"Public Offering","leadProduct":"VAX-24","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vaxcyte","amount2":0.85999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.85999999999999999,"dosageForm":"Injection","sponsorNew":"Vaxcyte \/ BofA Securities","highestDevelopmentStatusID":"8","companyTruncated":"Vaxcyte \/ BofA Securities"},{"orgOrder":0,"company":"Vaxcyte","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2024","type":"Public Offering","leadProduct":"VAX-24","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vaxcyte","amount2":0.75,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.85999999999999999,"dosageForm":"Injection","sponsorNew":"Vaxcyte \/ BofA Securities","highestDevelopmentStatusID":"8","companyTruncated":"Vaxcyte \/ BofA Securities"},{"orgOrder":0,"company":"Vaxcyte","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2024","type":"Public Offering","leadProduct":"VAX-24","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vaxcyte","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.85999999999999999,"dosageForm":"Injection","sponsorNew":"Vaxcyte \/ BofA Securities","highestDevelopmentStatusID":"8","companyTruncated":"Vaxcyte \/ BofA Securities"},{"orgOrder":0,"company":"Vaxcyte","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2024","type":"Not Applicable","leadProduct":"VAX-24","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vaxcyte","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Vaxcyte \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaxcyte \/ Not Applicable"},{"orgOrder":0,"company":"Vaxcyte","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2024","type":"Public Offering","leadProduct":"VAX-24","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Vaxcyte","amount2":1.3,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Vaxcyte \/ BofA Securities","highestDevelopmentStatusID":"14","companyTruncated":"Vaxcyte \/ BofA Securities"},{"orgOrder":0,"company":"Vaxcyte","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2024","type":"Public Offering","leadProduct":"VAX-24","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Vaxcyte","amount2":1.5,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Vaxcyte \/ BofA Securities","highestDevelopmentStatusID":"14","companyTruncated":"Vaxcyte \/ BofA Securities"},{"orgOrder":0,"company":"Vaxcyte","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2024","type":"Not Applicable","leadProduct":"31-valent Pneumococcal Conjugate Vaccine","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Vaxcyte","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Vaxcyte \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Vaxcyte \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals by Vaxcyte

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : VAX-31 is a 31-valent pneumococcal conjugate vaccine candidate which is under phase 1/2 clinical trials to prevent invasive pneumococcal disease, in healthy adults aged 50 and older.

                          Brand Name : VAX-31

                          Molecule Type : Vaccine

                          Upfront Cash : Not Applicable

                          November 12, 2024

                          Lead Product(s) : 31-valent Pneumococcal Conjugate Vaccine

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          02

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : The net proceeds will be used to fund clinical development of the VAX-24, a Phase 3-ready 24-valent, broad-spectrum for treating pneumococcal disease.

                          Brand Name : VAX-24

                          Molecule Type : Vaccine

                          Upfront Cash : Undisclosed

                          September 06, 2024

                          Lead Product(s) : VAX-24

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : BofA Securities

                          Deal Size : $1,500.0 million

                          Deal Type : Public Offering

                          blank

                          03

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : The net proceeds will be used to fund clinical development of the VAX-24, a Phase 3-ready 24-valent, broad-spectrum for treating pneumococcal disease.

                          Brand Name : VAX-24

                          Molecule Type : Vaccine

                          Upfront Cash : Undisclosed

                          September 04, 2024

                          Lead Product(s) : VAX-24

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : BofA Securities

                          Deal Size : $1,300.0 million

                          Deal Type : Public Offering

                          blank

                          04

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : Vaxcyte's VAX-24 is a 24-valent Pneumococcal conjugate vaccine, presently undergoing Phase II clinical trials specifically for infants to treat Invasive Pneumococcal disease.

                          Brand Name : VAX-24

                          Molecule Type : Vaccine

                          Upfront Cash : Not Applicable

                          March 04, 2024

                          Lead Product(s) : VAX-24

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          05

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : VAX-24 proceeds, for a Phase 3-ready 24-valent vaccine, will also fund VAX-31 pediatric and adult trials.

                          Brand Name : VAX-24

                          Molecule Type : Vaccine

                          Upfront Cash : Undisclosed

                          February 02, 2024

                          Lead Product(s) : VAX-24

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : BofA Securities

                          Deal Size : $862.5 million

                          Deal Type : Public Offering

                          blank

                          06

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : Proceeds for VAX-24, a 24-valent pneumococcal vaccine, Phase 3-ready, will also fund VAX-31 trials for adults and children.

                          Brand Name : VAX-24

                          Molecule Type : Vaccine

                          Upfront Cash : Undisclosed

                          January 30, 2024

                          Lead Product(s) : VAX-24

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : BofA Securities

                          Deal Size : $750.0 million

                          Deal Type : Public Offering

                          blank

                          07

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : Proceeds for VAX-24, a 24-valent broad-spectrum pneumococcal vaccine, Phase 3-ready, will fund adult and pediatric trials alongside VAX-31, a 31-valent next-gen vaccine.

                          Brand Name : VAX-24

                          Molecule Type : Vaccine

                          Upfront Cash : Undisclosed

                          January 30, 2024

                          Lead Product(s) : VAX-24

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : BofA Securities

                          Deal Size : Undisclosed

                          Deal Type : Public Offering

                          blank

                          08

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : VAX-31 is a 31-valent pneumococcal conjugate vaccine (PCV) candidate which is under phase 1/2 clinical trials to prevent invasive pneumococcal disease (IPD), in healthy adults aged 50 and older.

                          Brand Name : VAX-31

                          Molecule Type : Vaccine

                          Upfront Cash : Not Applicable

                          January 29, 2024

                          Lead Product(s) : 31-valent Pneumococcal Conjugate Vaccine

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          09

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : VAX-31 is an investigational 31-valent pneumococcal conjugate vaccine aimed at preventing invasive pneumococcal disease, especially in high-risk groups like infants and older adults.

                          Brand Name : VAX-31

                          Molecule Type : Vaccine

                          Upfront Cash : Not Applicable

                          January 04, 2024

                          Lead Product(s) : 31-valent Pneumococcal Conjugate Vaccine

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          10

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : Under the agreement, Vaxcyte obtains exclusive rights to independently develop and manufacture cell-free extract, a key component of the company’s 24-valent pneumococcal conjugate vaccine (PCV) franchise which includes VAX-24 and VAX-31.

                          Brand Name : VAX-24

                          Molecule Type : Vaccine

                          Upfront Cash : $135.0 million

                          November 27, 2023

                          Lead Product(s) : 24-valent Pneumococcal Conjugate Vaccine

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Recipient : Sutro Biopharma

                          Deal Size : $135.0 million

                          Deal Type : Agreement

                          blank